In order to demonstrate the general sensitivity of T-VEC to IFN-β and conversely show that NC tumor cells may be particularly amenable to immunovirotherapy with T-VEC due to possible defects in IFN signaling pathways, NC tumor cells were pretreated with IFN-β, before infection with T-VEC, and subsequently, anti-tumor efficacy was investigated. The gene discussed is IFNA1; the disease is infection.